Narrative review examines how AI and nanomedicine enhance management of pancreatic cancer, suggesting a new era in treatment.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies worldwide, characterized by late-stage diagnosis, aggressive progression, and limited therapeutic efficacy. With an overall five-year survival rate of merely 10% globally and approximately 510,922 new cases and 467,409 deaths reported in 2022, pancreatic cancer represents a formidable public health challenge . The convergence of artificial intelligence (AI) and nanomedicine heralds a transformative paradigm in oncology—termed“Smart Cancer Care”—that promises to revolutionize early detection, precise diagnosis, targeted drug delivery, and personalized treatment strategies. This narrative review examines the synergistic integration of AI-driven diagnostic platforms and nano-based therapeutic systems in the management of pancreatic cancer, exploring current advancements, clinical applications, and future trajectories toward precision oncology.
No takes yet. Share an insight, caveat, or question.
Khandelwal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: